Sign In

Login

Password

Forgot Password ? Sign Up

Debrisochina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Debrisochina" in Italian language version.

refsWebsite
Global rank Italian rank
14nih.gov
4th place
9th place
1oadoi.org
799th place
22nd place
1doi.org
2nd place
7th place

doi.org

dx.doi.org

nih.gov

ncbi.nlm.nih.gov

  • Abrams WB, Pocelinko R, Klausner M, Hanauer L, Whitman EN, Clinical pharmacological studies with debrisoquin sulfate, a new antihypertensive agent, in J New Drugs, vol. 38, 1964, pp. 268–83, PMID 14218621.
  • Clark DW, Genetically determined variability in acetylation and oxidation. Therapeutic implications, in Drugs, vol. 29, aprile 1985, pp. 342–75, PMID 2859977.
  • Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F, A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin, in Clin. Pharmacol. Ther., vol. 38, ottobre 1985, pp. 394–401, PMID 4042522.
  • Nakamura K, Goto F, Ray WA, et al., Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations, in Clin. Pharmacol. Ther., vol. 38, ottobre 1985, pp. 402–8, PMID 4042523.
  • Silas JH, Tucker GT, Smith AJ, Fieller NR, Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone, in Br J Clin Pharmacol, vol. 9, aprile 1980, pp. 419–25, PMC 1429981, PMID 7378259.
  • Lennard MS, Silas JH, Smith AJ, Tucker GT, Concentration of debrisoquine by human platelets in vivo: relationship to hypotensive effect [proceedings], in Br J Clin Pharmacol, vol. 4, ottobre 1977, pp. 635P, PMID 911620.
  • Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR, The disposition of debrisoquine in hypertensive patients, in Br J Clin Pharmacol, vol. 5, gennaio 1978, pp. 27–34, PMC 1429235, PMID 619932.
  • Luria MH, Freis ED, Treatment of hypertension with debrisoquin sulfate (Declinax), in Curr Ther Res Clin Exp, vol. 7, maggio 1965, pp. 289–96, PMID 14286208.
  • Heffernan AG, Carty AT, Clinical observations on the use of debrisoquine sulphate (Declinas) in the treatment of hypertension, in Ir J Med Sci, vol. 3, gennaio 1970, pp. 37–43, PMID 5444549.
  • Chen BT, Debrisoquine sulphate--a new antihypertensive agent with minimal side-effects, in Singapore Med J, vol. 12, aprile 1971, pp. 106–9, PMID 4945291.
  • (DE) Bückert A, Schweda E, Vich V, [Therapeutic results with the hypotensive agent Declinax (debrisoquin) in mild and medium forms of hypertension], in Schweiz. Rundsch. Med. Prax., vol. 62, novembre 1973, pp. 1453–60, PMID 4202234.
  • Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE, Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects, in Clin. Pharmacol. Ther., vol. 50, settembre 1991, pp. 308–13, PMID 1680593.
  • Straka RJ, Hansen SR, Walker PF, Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota, in Clin. Pharmacol. Ther., vol. 58, luglio 1995, pp. 29–34, DOI:10.1016/0009-9236(95)90069-1, PMID 7628180.
  • Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL, Genetically determined oxidation capacity and the disposition of debrisoquine, in Br J Clin Pharmacol, vol. 15, aprile 1983, pp. 443–50, PMC 1427798, PMID 6849780.

oadoi.org